Skip to main content
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. — Investor Relations & Filings

Ticker · VKTX ISIN · US92686J1060 LEI · 529900IVC72YPFA25M37 US Professional, scientific and technical activities
Filings indexed 608 across all filing types
Latest filing 2025-08-19 Regulatory Filings
Country US United States of America
Listing US VKTX

About Viking Therapeutics, Inc.

https://vikingtherapeutics.com/

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's pipeline is centered on small molecule drug candidates designed to address these conditions.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or disclosures by a company. The text specifically mentions that the filing is a Current Report pursuant to the Securities Exchange Act of 1934, dated August 19, 2025. It includes a press release announcing top-line results from a Phase 2 clinical trial, furnished as an exhibit. There are no detailed financial statements or comprehensive financial data included in the text. The document is relatively short (3553 characters) and primarily serves as an announcement of a press release rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events or disclosures without detailed financial data.
2025-08-19 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-06 English
10-Q
Interim / Quarterly Report Q2 2025
2025-07-23 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 23, 2025, reporting financial results for the second quarter ended June 30, 2025. It specifically states that it includes a press release with financial results and a corporate update. The document is relatively short (3893 characters) and primarily serves as a current report to announce quarterly financial results. This matches the characteristics of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. It is not a full interim report (IR) with comprehensive financial statements, nor is it an Annual Report (10-K). Therefore, the correct classification is Earnings Release (ER).
2025-07-23 English
4
Director's Dealing
2025-07-03 English
4
Director's Dealing
2025-07-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.